Pangenomic Health Inc.

Equities

NARA

CA69842E3041

Advanced Medical Equipment & Technology

Delayed Canadian Securities Exchange Other stock markets 10:27:36 2024-04-30 am EDT			5-day change	1st Jan Change
0.08 ^CAD	0.00%		0.00%	-60.00%

Feb. 19	PanGenomic Health plans to withdraw shares from Aquis Stock Exchange	AN
Feb. 16	Pangenomic Health Inc. Announces Changes to Board of Directors	CI

PanGenomic Health buys CyberPatient licence for exclusive use

June 02, 2023 at 03:34 am EDT

PanGenomic Health Inc - Vancouver, Canada-based precision health company - Enters a non-binding letter of intent on Tuesday with Interactive Health Inc, where it will license IHI's CyberPatient AI medical education platform. The licensing is for the exclusive use in the consumer, public health, and complementary and alternative medicine sectors, the firm says. Says it will buy the CyberPatient licence from IHI for an aggregate purchase price of CAD5.3 million, or about GBP3.2 million.

Chief Executive Officer Maryam Marissen says: "We are thrilled to welcome the CyberPatient AI Platform to PanGenomic. Its digital twin technology will enhance our Nara self-care platform, providing a personalized, visual health journey for our users. It is an important step in empowering individuals and their natural healthcare practitioners with cutting-edge tools to better understand and utilize multi-dimensional health data, AI insights, and genomic data, contributing to our mission of improving health care through advanced technology."

Current stock price: CAD0.06

12-month change: down 78%

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Pangenomic Health Inc.

PanGenomic Health plans to withdraw shares from Aquis Stock Exchange	Feb. 19	AN
Pangenomic Health Inc. Announces Changes to Board of Directors	Feb. 16	CI
PanGenomic Health agrees non-binding drawdown facility with Crescita	Jan. 09	AN
PanGenomic subsidiary reveals point-of-care vitamin D test	Dec. 06	AN
PanGenomic Health Subsidiary Introducing Point-of-Care Vitamin D Test for Dental Implant Industry	Dec. 06	MT
Pangenomic Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
PanGenomic Health's MUJN sells first biomarker tests	Nov. 17	AN
PanGenomic Health interim loss widens amid higher costs	23-08-30	AN
Pangenomic Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Pangenomic Health Inc. Announces Director Resignations	23-07-13	CI
PanGenomic subsidiary begins health assessment service	23-07-07	AN
Pangenomic Health Inc. Announces Management Changes	23-07-06	CI
Pangenomic Health Inc. Provides Update for Nara Product and Conversational Ai	23-06-06	CI
PanGenomic Health buys CyberPatient licence for exclusive use	23-06-02	AN
Pangenomic Health Inc. Signs Non-Binding Letter of Intent for an Exclusive Special Purpose Licence of the Cyberpatient Ai Medical Education Platform	23-05-30	CI
Pangenomic Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
PanGenomic Health annual loss widens but "very pleased" with progress	23-05-03	AN
Pangenomic Health Inc. Auditor Raises 'Going Concern' Doubt	23-04-30	CI
Pangenomic Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-30	CI
Pangenomic Health Inc. Launches Its New Visual Identity, Website and E-Commerce Store for Its NARA Brand	23-02-09	CI
Pangenomic Health Subsidiary Signs Rental Agreement with Psy Integrated Health, Makes Progress Towards Development of Joint Testing Facility	23-02-02	CI
PanGenomic Health Inc. Announces its Nara Plant Library is Available Now on the Nara App	23-01-23	CI
PanGenomic Health Announces Soft Launch of NARA Personalized DNA Reports, Closes Private Placement	23-01-20	MT
Pangenomic Health Inc. announced that it has received CAD 0.51225 million in funding	23-01-19	CI
Pangenomic Health Inc. to Launch E-Commerce Platform for Personalized Natural Health	23-01-09	CI

Chart Pangenomic Health Inc.

Duration

Period

More charts

Company Profile

Pangenomic Health Inc. is a precision health company. The Company, through its subsidiaries, is engaged in developing a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Its products include a mobile app for consumers (Nara), a telehealth mental health app and telehealth platform for consumers (Mindleap) and a clinical decision support platform for health practitioners (MUJN). The Nara mobile app provides consumers with a knowledge base, which is based on individual's user profile, leveraging input from mental health questionnaires, drug treatment regimen, genomic sequencing analysis, as well as their protein and microbiome biomarker reports. The Mindleap platform provides a variety of tools and resources to help individuals understand and improve their inner wellness. The MUJN clinical decision support platform provides health practitioners with access to the consumer's mobile app data and their diagnostic reports.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Medical Software & Technology Services

	1st Jan change	Capi.
PANGENOMIC HEALTH INC.	-60.00%	615K
VEEVA SYSTEMS INC.	+3.83%	32.58B
PRO MEDICUS LIMITED	+16.26%	7.65B
SECTRA AB	+21.60%	3.92B
EVOLENT HEALTH, INC.	-15.56%	3.19B
OMNICELL, INC.	-28.14%	1.26B
LUNIT INC.	-31.01%	1.14B
B-SOFT CO.,LTD.	-34.81%	926M
SIMULATIONS PLUS, INC.	+0.54%	908M
VERADIGM INC.	-22.78%	859M

Medical Software & Technology Services